文献速递淋巴瘤

人工智能增强流式细胞术数据加速检出可测量残留慢性淋巴细胞白血病

Artificial intelligence-enhancement of flow cytometry data accelerates the identification of measurable residual chronic lymphocytic leukemia.
PubMed 文献 · Leukemia · 2026-05-26

研究开发AI流程CCADDAS,对166例MRD阳性与61例MRD阴性的CLL流式细胞术文件进行自动纠错、聚类、降维、异常检测与降采样,并训练深度神经网络自动设门。AI增强结果与专家人工分析高度一致(R²=0.98),每例分析时间由9.0分钟降至0.9分钟,降低90%。

要点

  • AI增强流式结果与专家人工分析高度一致(R²=0.98)
  • 降采样使细胞量减少85%、文件体积减少78%,仍保留低水平MRD事件
  • 每例人工分析时间由9.0分钟降至0.9分钟,减少90%

核心结论

  • CCADDAS提供基本无监督、不依赖特定软件的方法,在不劣于常规分析的前提下加速并简化CLL MRD检测,利于流式MRD检测的推广。

研究设计与样本

  • 开发AI流程CCADDAS,使用单管10色panel,在云环境处理166例MRD阳性和61例MRD阴性病例的流式文件。
  • 自动步骤包括FlowCut纠错、PARC聚类、UMAP降维、对照阴性样本的异常检测,以及保留罕见MRD事件的聚类信息降采样。
  • 以专家定义的正常亚群训练深度神经网络,实现自动设门。

主要发现

  • AI增强文件在标准流式软件中分析,结果与常规专家复核高度一致(R²=0.98)。
  • 降采样使细胞量减少85%、文件大小减少78%,同时保留低水平MRD事件。
  • AI生成的异常度量表区分CLL MRD与背景B细胞性能优异(AUC=0.98)。
  • 每例人工分析时间从9.0分钟降至0.9分钟(减少90%)。

临床怎么用

  • 可在常规流式软件中读取AI增强文件,用自动设门与异常评分辅助CLL MRD判读,缩短人工分析时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Flow cytometry (FC) is essential for detecting measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL), but its use is limited by the expertise and time required for manual analysis. We developed an artificial intelligence (AI) pipeline, Clustering/Classification of All Events, Dimensionality reduction, Downsampling, and Aberrancy Scaling (CCADDAS), to automatically enhance raw FC files, streamlining CLL MRD detection using a single-tube 10-color panel. FC files from 166 MRD-positive and 61 MRD-negative cases were processed in a cloud environment. Automated steps included error correction (FlowCut), clustering (PARC), dimensionality reduction (UMAP), anomaly detection against negative controls, and cluster-informed downsampling that preserved rare MRD events. A deep neural network trained on expert-defined normal subsets enabled automated gating. AI-enhanced files were analyzed in standard FC software, yielding results highly concordant with conventional expert review (R² = 0.98). Downsampling reduced cellularity by 85% and file size by 78%, while retaining low-level MRD events. An AI-generated aberrancy scale distinguished CLL MRD from background B cells with excellent performance (AUC = 0.98). Manual analysis time decreased from 9.0 to 0.9 min per case (90% reduction). CCADDAS provides a largely unsupervised, software-agnostic method that accelerates and simplifies CLL MRD detection without compromising test performance compared to conventional analysis, enabling broader adoption of FC-based MRD testing.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Chiu A, Seheult JN, Shi M, et al. Artificial intelligence-enhancement of flow cytometry data accelerates the identification of measurable residual chronic lymphocytic leukemia. Leukemia. 2026. PMID: 42192141. doi:10.1038/s41375-026-02986-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。